Last Updated: November 16, 2026

mavacamten - Profile

« Back to Dashboard


What are the generic drug sources for mavacamten and what is the scope of patent protection?

Mavacamten is the generic ingredient in one branded drug marketed by Bristol and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Summary for mavacamten
International Patents:67
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for mavacamten
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for mavacamten
Generic Entry Date for mavacamten*:
Constraining patent/regulatory exclusivity:
Dosage:

CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for MAVACAMTEN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
CAMZYOS Capsules mavacamten 2.5 mg, 5 mg, 10 mg and 15 mg 214998 7 2026-04-28

US Patents and Regulatory Information for mavacamten

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol CAMZYOS mavacamten CAPSULE;ORAL 214998-005 Sep 30, 2026 RX Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Bristol CAMZYOS mavacamten CAPSULE;ORAL 214998-001 Apr 28, 2022 RX Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Bristol CAMZYOS mavacamten CAPSULE;ORAL 214998-001 Apr 28, 2022 RX Yes No ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
Bristol CAMZYOS mavacamten CAPSULE;ORAL 214998-001 Apr 28, 2022 RX Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Bristol CAMZYOS mavacamten CAPSULE;ORAL 214998-001 Apr 28, 2022 RX Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for mavacamten

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Bristol-Myers Squibb Pharma EEIG Camzyos mavacamten EMEA/H/C/005457Treatment of symptomatic obstructive hypertrophic cardiomyopathy. Authorised no no no 2023-06-26
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for mavacamten

Country Patent Number Title Estimated Expiration
Australia 2014281408 Pyrimidinedione compounds against cardiac conditions ⤷  Start Trial
Australia 2018264088 Pyrimidinedione compounds against cardiac conditions ⤷  Start Trial
Australia 2020204271 Pyrimidinedione compounds against cardiac conditions ⤷  Start Trial
Australia 2022202298 Pyrimidinedione compounds against cardiac conditions ⤷  Start Trial
Brazil 112015031864 compostos de pirimidinadiona contra as condições cardíacas ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for mavacamten

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3010910 PA2023535,C3010910 Lithuania ⤷  Start Trial PRODUCT NAME: MAVAKAMTENAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/23/1716 20230626
3010910 C03010910/01 Switzerland ⤷  Start Trial PRODUCT NAME: MAVACAMTENUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68477 25.04.2023
3010910 PA2023535 Lithuania ⤷  Start Trial PRODUCT NAME: MAVAKAMTENAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/23/1716 20230626
3010910 2390030-1 Sweden ⤷  Start Trial PRODUCT NAME: MAVACAMTEN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/23/1716 20230627
3010910 202340028 Slovenia ⤷  Start Trial PRODUCT NAME: MAVACAMTEN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NATIONAL AUTHORISATION NUMBER: EU/1/23/1716; DATE OF NATIONAL AUTHORISATION: 20230626; AUTHORITY FOR NATIONAL AUTHORISATION: EU
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Mavacamten (Camzyos) Investment Scenario and Fundamentals

Last updated: April 23, 2026

Mavacamten (Camzyos) is a myosin inhibitor for symptomatic New York Heart Association (NYHA) class II to III obstructive hypertrophic cardiomyopathy (oHCM). Core investment framing: (1) reimbursement and payer coverage pace in the US, (2) persistence and dose optimization outcomes that drive durable demand, (3) label and guideline uptake tied to safety and monitoring burden, and (4) pipeline value from next indications and next-generation myosin programs.

What does mavacamten treat, and what is the commercial anchor?

Mavacamten is approved for adults with symptomatic, NYHA class II-III oHCM. The approved indication is specifically for obstructive disease; it requires patient selection and ongoing monitoring because the drug can reduce cardiac function.

US label baseline (commercial anchor)

  • Indication: symptomatic NYHA class II to III obstructive HCM in adults
  • Mechanism: cardiac myosin inhibitor
  • Monitoring concept: echocardiography-guided dosing with ejection fraction and hemodynamic assessment (label requirement)

Competitive context (positioning)

  • oHCM options are dominated by beta-blockers and calcium-channel blockers, with disopyramide in some cases and invasive septal reduction therapies (surgical myectomy, alcohol septal ablation) used when medical therapy fails.
  • Mavacamten shifts treatment from “symptom management plus procedure” toward a pharmacologic disease-modifying approach in selected patients, with demand tied to outcomes and the feasibility of chronic monitoring.

What are the demand drivers and investor KPIs?

For a specialty cardiovascular drug with a monitoring protocol, the fundamentals cluster into adoption, retention, and unit economics. The KPIs below drive valuation more than headline trial performance once commercialization begins.

1) Prescriber adoption and patient start rate

  • Start rate is primarily a function of referral pathways to specialized cardiology centers, comfort with echo titration, and payer authorization speed.
  • Dose titration cadence and the need for recurrent echocardiograms raise friction that affects early conversion from prescriptions to ongoing therapy.

2) Persistence and dose stability

  • Myosin inhibition shows meaningful variability with dosing and drug interactions; persistence depends on whether patients achieve durable symptom relief without excessive dose holds.
  • Investor-relevant metrics include:
    • time on therapy (TOT)
    • fraction of patients stable at maintenance dose
    • dose interruptions per quarter tied to protocol constraints

3) Coverage and net price

  • In the US, net price hinges on formulary status and prior authorization requirements. For specialty drugs, the path to broad coverage often determines peak sales trajectory.
  • Net price is also influenced by pharmacy benefit design and contracting behavior once payer formularies settle after initial launches.

4) Clinical outcomes that translate to payer value

  • Payers and health systems focus on hospital utilization, functional status improvement, and the ability to defer septal reduction.
  • In oHCM, “utility” is not only symptom scores; it includes reduction in gradient/hemodynamics and improvements that reduce escalation of care.

5) Safety and monitoring burden

  • The label includes risk mitigation around cardiac function, requiring adherence to echocardiographic monitoring and dosing interruption rules.
  • Safety signals that increase discontinuations or trigger more frequent dose changes can reduce effective demand even if prescriptions remain stable.

What is the clinical performance basis behind market uptake?

Mavacamten’s value proposition is built on controlled evidence that it reduces the left ventricular outflow tract gradient and improves symptoms in oHCM. In commercialization, those endpoints matter insofar as they predict real-world persistence.

Key evidence landmarks (development to label)

  • EXPLORER-HCM (Phase 2) established feasibility and dose-response for gradient reduction and symptom outcomes.
  • PIONEER-HCM (Phase 3) evaluated mavacamten in patients with obstructive HCM, with endpoints anchored to hemodynamic response and functional improvement. (Trial reporting is the basis for approval and label dosing concepts.)
  • Ongoing and subsequent studies support refinement of dosing and durability of benefit.

(Clinical evidence sources are reflected in the product labeling and trial disclosures listed in the reference section.)

What is the investment scenario: bull, base, and bear?

Below is a structured investment scenario using the known dynamics of a specialty, monitoring-heavy cardiovascular therapy. These scenarios are directional frameworks tied to observable commercial and clinical execution factors.

Bull case (execution + payer normalization)

  • Rapid payer coverage broadens eligible patient volume beyond specialty centers.
  • Start rate rises as authorization pathways stabilize.
  • Persistence improves as dose titration algorithms and clinician familiarity reduce holds.
  • Clinical outcomes translate into fewer escalations to septal reduction procedures in payer-aligned cohorts.

Net impact: higher cumulative prescriptions per covered patient and improved revenue ramp.

Base case (steady penetration, monitoring remains a constraint)

  • Coverage expands gradually; authorization remains common.
  • Start rate grows, but titration friction keeps early ramp moderate.
  • Persistence is “healthy but not optimal,” with ongoing dose holds consistent with label monitoring.
  • Outcomes meet expectations, but variation in dosing management affects conversion from symptomatic improvement to durable therapy.

Net impact: sustained growth with volatility tied to real-world titration adherence and payer contracting cycles.

Bear case (safety friction + payer pushback)

  • Payer coverage lags; net price discounts intensify.
  • More patients discontinue due to cardiac function constraints or inconvenient monitoring cadence.
  • Dose holds increase, reducing effective dose intensity and symptom benefit in practice.
  • Clinician adoption is slower if echo monitoring capacity is constrained.

Net impact: lower persistence and lower net revenue per treated patient, capping peak sales.

Where does mavacamten face value leakage?

1) Monitoring friction and system capacity

Echocardiography-led dosing can bottleneck adoption if care pathways are not standardized. Even when the product works, logistical friction can reduce conversion and persistence.

2) Interaction and dosing complexity

Myosin inhibitors are sensitive to dosing adjustments and interaction management. In real-world practice, drug interactions and co-medication patterns can increase dose holds.

3) Evidence translation to community settings

Trial performance is achieved under protocol-driven care. Community cardiology varies in adherence to titration schedules, echo read consistency, and follow-up intensity.

4) Procedure substitution risk

If some patients remain steered toward septal reduction therapies, mavacamten penetration can cap, especially when procedural outcomes are favorable for subgroups.

What are the competitive and pipeline considerations?

Competitive field

  • oHCM is not a high-volume oncology-like market but has a meaningful number of eligible patients concentrated in cardiology centers.
  • Competition is less about head-to-head randomized trials against a single drug and more about decision-making versus:
    • chronic medical management
    • disopyramide for select patients
    • septal reduction procedures

Pipeline leverage

From an investment perspective, valuation should consider any confirmed or credible expansion efforts from:

  • oHCM subgroup refinement
  • broader cardiomyopathy phenotypes
  • next-generation myosin inhibitor programs

The market will treat any meaningful expansion as incremental addressable volume. In contrast, any safety constraint that expands monitoring burden can depress near-term economics even if clinical benefit holds.

What should investors watch in earnings and regulatory updates?

Commercial execution watchlist

  1. Prescriber and treatment reach
    • new starts per quarter
    • proportion of patients on maintenance dose
  2. Titration and hold rates
    • dose interruption frequency
    • percentage of patients requiring repeated titration cycles
  3. Net sales vs gross growth
    • payer discount intensity
    • channel mix
  4. Real-world safety and discontinuations
    • adverse events leading to discontinuation
  5. Center-of-excellence expansion
    • growth in initiating sites beyond core institutions

Regulatory and label watchlist

  • any label updates that modify:
    • eligibility criteria
    • monitoring frequency
    • dosing limits
    • contraindications or interaction management

How to think about valuation without relying on uncertain numbers

Investment-grade fundamental work for mavacamten should focus on drivers that can be observed and tracked each quarter rather than relying on generic revenue forecasts.

Practical valuation linkage

  • Higher starts drive revenue growth only if persistence and dose stability follow.
  • Higher net price helps but cannot offset a steep persistence decline caused by monitoring friction or safety events.
  • Pipeline or label expansions can lift peak sales expectations but matter most once commercialization execution already supports consistent base growth.

Key Takeaways

  • Mavacamten is a specialty, monitoring-dependent cardiomyopathy drug with demand governed by payer coverage, clinician adoption, titration friction, and persistence under label dosing constraints.
  • The investment scenario hinges less on trial headline endpoints and more on quarterly operational KPIs: starts, maintenance stabilization, dose hold rates, net price movement, and discontinuations.
  • Bull cases require payer normalization plus dose titration efficiencies; base cases require steady adoption with manageable monitoring friction; bear cases show up as higher discontinuations, tighter net pricing, and slower start rates.

FAQs

1) What is mavacamten’s approved use?
It is approved in adults with symptomatic NYHA class II to III obstructive hypertrophic cardiomyopathy. (Source: US prescribing information.)

2) Why does monitoring matter for investment fundamentals?
Label-directed echocardiography and dose titration affect clinician workflow and dosing continuity, which drives persistence, discontinuation, and effective revenue per treated patient. (Source: US prescribing information.)

3) What drives payer coverage for mavacamten?
Coverage depends on formulary status, prior authorization requirements, and evidence of clinical and functional benefit that supports value. (Source: US prescribing information and clinical development context.)

4) How does mavacamten compete in oHCM?
It competes against ongoing medical therapy and against escalation to septal reduction procedures, with adoption influenced by monitoring feasibility and real-world outcomes. (Source: clinical context reflected in labeling and trial programs.)

5) What is the most important KPI after launch?
Persistence and dose stability (maintenance dosing with manageable dose holds) after initial titration, because they determine lifetime net sales more than one-time prescriptions. (Source: dosing and monitoring requirements in prescribing information.)


References (APA)

[1] Bristol Myers Squibb. (2024). Camzyos (mavacamten) prescribing information. https://www.camzyos.com/
[2] Olivotto, I., et al. (2020). EXPLORER-HCM: mavacamten in obstructive hypertrophic cardiomyopathy (clinical study results). (Trial publication).
[3] Greenberg, B., et al. (2020). PIONEER-HCM: mavacamten in obstructive hypertrophic cardiomyopathy (phase 3 clinical study results). (Trial publication).
[4] Teirstein, P. S., et al. (2023). Longer-term follow-up of mavacamten in obstructive hypertrophic cardiomyopathy. (Publication).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.